Immunology Seminar: Jalkanen
March 5th at 14:00
Online event
in Zoom
Sirpa Jalkanen, Professor, Academian, University of Turku
The thrill of searching and joy of finding
Host: Riitta Lahesmaa (rilahes@utu.fi)
Join the Zoom: https://utu.zoom.us/j/63424930809
Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience. For further information contact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi), University of Turku.
Academician Sirpa Jalkanen, MD, PhD is Professor at the Medical Faculty, University of Turku. After her postdoctoral period at Stanford University, she has worked in different researcher positions at the University of Turku, Finnish National Institute of Health and Welfare as well as the Academy of Finland. The main interest of Sirpa Jalkanen’s research group has been in the mechanisms involved in harmful inflammations and cancer. Her group has identified several molecules, some of which are currently targeted in clinical trials. She has published more than 390 peer-reviewed papers and has more than 10 patents. She is an EMBO member and a member of Academia Europae and has received several awards and honours such as Eli Lilly award, Maud Kuistila Prize, Anders Jahre Prize, Äyräpää Prize, Klossner Medal, Datta Medal (from FEBS), the 2nd European Women Innovator Prize and the Finnish Pharma Industry Prize.
Selected publications
Tadayon S, Dunkel J, Takeda A, Halle O, Karikoski M, Gerke H, Rantakari P, Virtakoivu R, Pabst O, Salmi M, Hollmén M*, Jalkanen S*. Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunol 4:eaat0297, 2019.
Takeda A, Hollmén M, Dermadi D, Pan J, Brulois KF, Kaukonen R, Lönnberg T, Boström P, Koskivuo I, Irjala H, Miyasaka M, Salmi M, Butcher EC, Jalkanen S. Single-cell survey of human lymphatics unveils unexpected heterogeneity and mechanisms of homing for neutrophils. Immunity 51:561-572, 2019.
Jalkanen J, Pettilä V, Huttunen T, Hollmen M, Jalkanen S. Glucocorticoids Inhibit Type I IFN Beta Signaling and the Upregulation of CD73 in Human Lung. Intensive Care Med 46:1937-1940, 2020.
Jalkanen J, Khan S, Elima K, Huttunen T, Wang N, Hollmén M, Elo LL, Jalkanen S. Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19. Critical Care 27:112, 2023.